85% of Online Europeans Use the Internet for Health Information

Manhattan ResearchIn 2009, 85% of online Europeans in the United Kingdom, Germany, France, Italy, and Spain turn to the Internet and other technologies for health and prescription drug information, according to the latest Cybercitizen Health® Europe v9.0 study from healthcare and pharmaceutical market research company Manhattan Research. The collaboratively-edited Wikipedia again proves to be a top online health resource for consumers in all of the countries surveyed.

Cybercitizen Health® Europe v9.0 is a market research and strategic advisory service focused on how European consumers use digital channels for health and the impact on treatment decisions. Key topics include the overall health media mix, search engine reliance, pharmaceutical product websites, health portals, health information-seeking methods, email communication, patient-physician interactions, mobile devices, social media, disease management tools, and more.

"This year's Cybercitizen Health® Europe is the third iteration of the study, and our 2009 findings show that now more than ever, it's critical for healthcare and pharmaceutical companies across Europe to gain a strong understanding of how their target audiences use the Internet," said Mark Bard, president of Manhattan Research. "Marketers already know that an increasing number of consumers are going online for health - the key is having the market research tools for turning Health 2.0 buzz into effective and efficient strategies for connecting with patients online."

Complimentary European eHealth White Paper
To download a complimentary white paper reviewing the European eHealth landscape, please visit: www.manhattanresearch.com/research/white-papers/european-ehealth-landscape.aspx.

About Cybercitizen Health® Europe
Cybercitizen Health® Europe is a syndicated multi-client study and advisory service focused on key research topics and trends impacting the European consumer health marketplace - with the goal of enabling companies to make better informed decisions when planning and executing marketing strategies. The study was fielded online in Q3 2009 among 3,007 European consumers from the United Kingdom, Germany, Spain, Italy, and France. For additional product information, please visit www.manhattanresearch.com/ccheu.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers in the United States, Europe and Asia. For information, visit www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...